Ketamine Can Rapidly Reduce Suicidal Thoughts
|
By HospiMedica International staff writers Posted on 01 Jan 2018 |
|
Image: According to a new study, ketamine can rapidly reduce suicidal thoughts in the depressed (Photo courtesy of Erowid).
Ketamine is significantly more effective and much faster in reducing suicidal ideation in depressed patients than sedatives, according to a new study.
Researchers at Columbia University Medical Center (CUMC; New York, NY, USA) conducted a clinical trial in 80 adults with a current major depressive disorder and a Scale for Suicidal Ideation (SSI) score higher than 4 in order to test the acute effect of adjunctive, sub-anesthetic intravenous ketamine administration on clinical suicidal ideation. The patients, of whom 54% were taking antidepressant medication, were randomly assigned to receive either a ketamine or a midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion.
The results revealed that within 24 hours, more patients in the ketamine group had a 50% reduction in suicidal thoughts (55%) than in the midazolam group (30%), as measured by SSI, with improvements persisting for up to six weeks. Those in the ketamine group also had greater improvement in overall mood, depression, and fatigue. Ketamine's effect on depression accounted for approximately one-third of its effect on suicidal thoughts, suggesting the treatment has a specific anti-suicidal effect. The study was published on December 5, 2017, in the American Journal of Psychiatry.
“There is a critical window in which depressed patients who are suicidal need rapid relief to prevent self-harm. Currently available antidepressants can be effective in reducing suicidal thoughts in patients with depression, but they can take weeks to have an effect,” said lead author Michael Grunebaum, MD. “Suicidal, depressed patients need treatments that are rapidly effective in reducing suicidal thoughts when they are at highest risk. Ketamine offers promise as a rapidly acting treatment for reducing suicidal thoughts in patients with depression.”
Ketamine is a rapidly acting dissociative anesthetic agent that can provide analgesia, sedation, and amnesia for rapid sequence intubation in critically ill patients. Short- and long-term effects include increased heart rate and elevated blood pressure, nausea, vomiting, numbness, depression, amnesia, hallucinations, and potentially fatal respiratory problems. Sub-anesthetic ketamine is often administered intraoperatively for postoperative analgesia due to the detached, dreamlike state it creates.
Related Links:
Columbia University Medical Center
Researchers at Columbia University Medical Center (CUMC; New York, NY, USA) conducted a clinical trial in 80 adults with a current major depressive disorder and a Scale for Suicidal Ideation (SSI) score higher than 4 in order to test the acute effect of adjunctive, sub-anesthetic intravenous ketamine administration on clinical suicidal ideation. The patients, of whom 54% were taking antidepressant medication, were randomly assigned to receive either a ketamine or a midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion.
The results revealed that within 24 hours, more patients in the ketamine group had a 50% reduction in suicidal thoughts (55%) than in the midazolam group (30%), as measured by SSI, with improvements persisting for up to six weeks. Those in the ketamine group also had greater improvement in overall mood, depression, and fatigue. Ketamine's effect on depression accounted for approximately one-third of its effect on suicidal thoughts, suggesting the treatment has a specific anti-suicidal effect. The study was published on December 5, 2017, in the American Journal of Psychiatry.
“There is a critical window in which depressed patients who are suicidal need rapid relief to prevent self-harm. Currently available antidepressants can be effective in reducing suicidal thoughts in patients with depression, but they can take weeks to have an effect,” said lead author Michael Grunebaum, MD. “Suicidal, depressed patients need treatments that are rapidly effective in reducing suicidal thoughts when they are at highest risk. Ketamine offers promise as a rapidly acting treatment for reducing suicidal thoughts in patients with depression.”
Ketamine is a rapidly acting dissociative anesthetic agent that can provide analgesia, sedation, and amnesia for rapid sequence intubation in critically ill patients. Short- and long-term effects include increased heart rate and elevated blood pressure, nausea, vomiting, numbness, depression, amnesia, hallucinations, and potentially fatal respiratory problems. Sub-anesthetic ketamine is often administered intraoperatively for postoperative analgesia due to the detached, dreamlike state it creates.
Related Links:
Columbia University Medical Center
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Medical Examination & Procedure Light
Vega 80
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Latest Critical Care News
- Automated IV Labeling Solution Improves Infusion Safety and Efficiency
- First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
- 4D Digital Twin Heart Model Improves CRT Outcomes
- AI Turns Glucose Data Into Actionable Insights for Diabetes Care
- Microscale Wireless Implant Tracks Brain Activity Over Time
- Smart Mask Delivers Continuous, Battery-Free Breath Monitoring
- Routine Blood Pressure Readings May Identify Risk of Future Cognitive Decline
- CGM-Based Algorithm Enhances Insulin Dose Adjustment in Type 2 Diabetes
- Fish Scale–Based Implants Offer New Approach to Corneal Repair
- Dual-Function Wound Patch Combines Infection Sensing and Treatment
- Smartwatch Signals and Blood Tests Team Up for Early Warning on Insulin Resistance
- Smart Fabric Technology Aims to Prevent Pressure Injuries in Hospital Care
- Standardized Treatment Algorithm Improves Blood Pressure Control
- Combined Infection Control Strategy Limits Drug-Resistant Outbreak in NICU
- AI Helps Predict Which Heart-Failure Patients Will Worsen Within a Year
- Algorithm Allows Paramedics to Predict Brain Damage Risk After Cardiac Arrest
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read more
Surgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
